Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Pratley

Showing results (51-60 of 69) with videos related to

Pageof 7
Sort By:
Canadian Journal of Diabetes|July 3, 2026
Characterizing subjective sleep quality and sleep apnea risk in adults with type 1 diabetesMiranda Zuniga-Kennedy, Devon Hansen, Jane D Bulger, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 18, 2023
The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney diseasePeter Rossing, Florian M M Baeres, George Bakris, et al.
The New England Journal of Medicine|September 23, 2020
Cardiovascular Outcomes with Ertugliflozin in Type 2 DiabetesChristopher P Cannon, Richard Pratley, Samuel Dagogo-Jack, et al.
Plos One|March 25, 2021
ICU outcomes and survival in patients with severe COVID-19 in the largest health care system in central FloridaEduardo Oliveira, Amay Parikh, Arnaldo Lopez-Ruiz, et al.
Journal of Diabetes Science and Technology|December 24, 2019
Hypoglycemia and Glycemic Control in Older Adults With Type 1 Diabetes: Baseline Results From the WISDM StudyAnders L Carlson, Lauren G Kanapka, Kellee M Miller, et al.
The Journal of Clinical Endocrinology and Metabolism|January 20, 2020
Risk Factors for Cardiovascular Disease (CVD) in Adults with Type 1 Diabetes: Findings from Prospective Real-life T1D Exchange RegistryViral N Shah, Ryan Bailey, Mengdi Wu, et al.
Lancet (London, England)|September 2, 2024
Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trialsMikhail N Kosiborod, John Deanfield, Richard Pratley, et al.
The Lancet. Diabetes & Endocrinology|September 18, 2020
Diabetes in ageing: pathways for developing the evidence base for clinical guidanceMedha N Munshi, Graydon S Meneilly, Leocadio Rodríguez-Mañas, et al.
European Heart Journal|August 30, 2024
Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trialKenneth W Mahaffey, Katherine R Tuttle, Mustafa Arici, et al.
Diabetes Research and Clinical Practice|April 10, 2026
Plasma biomarkers of neurodegeneration and their associations with type 1 diabetes characteristics and glycemiaNikki Delgado, Naomi S Chaytor, Michal Schnaider Beeri, et al.
Pageof 7

Showing results (51-60 of 69) with videos related to

Sort By:
Pageof 7
Canadian Journal of Diabetes|July 3, 2026
Characterizing subjective sleep quality and sleep apnea risk in adults with type 1 diabetesMiranda Zuniga-Kennedy, Devon Hansen, Jane D Bulger, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 18, 2023
The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney diseasePeter Rossing, Florian M M Baeres, George Bakris, et al.
The New England Journal of Medicine|September 23, 2020
Cardiovascular Outcomes with Ertugliflozin in Type 2 DiabetesChristopher P Cannon, Richard Pratley, Samuel Dagogo-Jack, et al.
Plos One|March 25, 2021
ICU outcomes and survival in patients with severe COVID-19 in the largest health care system in central FloridaEduardo Oliveira, Amay Parikh, Arnaldo Lopez-Ruiz, et al.
Journal of Diabetes Science and Technology|December 24, 2019
Hypoglycemia and Glycemic Control in Older Adults With Type 1 Diabetes: Baseline Results From the WISDM StudyAnders L Carlson, Lauren G Kanapka, Kellee M Miller, et al.
The Journal of Clinical Endocrinology and Metabolism|January 20, 2020
Risk Factors for Cardiovascular Disease (CVD) in Adults with Type 1 Diabetes: Findings from Prospective Real-life T1D Exchange RegistryViral N Shah, Ryan Bailey, Mengdi Wu, et al.
Lancet (London, England)|September 2, 2024
Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trialsMikhail N Kosiborod, John Deanfield, Richard Pratley, et al.
The Lancet. Diabetes & Endocrinology|September 18, 2020
Diabetes in ageing: pathways for developing the evidence base for clinical guidanceMedha N Munshi, Graydon S Meneilly, Leocadio Rodríguez-Mañas, et al.
European Heart Journal|August 30, 2024
Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trialKenneth W Mahaffey, Katherine R Tuttle, Mustafa Arici, et al.
Diabetes Research and Clinical Practice|April 10, 2026
Plasma biomarkers of neurodegeneration and their associations with type 1 diabetes characteristics and glycemiaNikki Delgado, Naomi S Chaytor, Michal Schnaider Beeri, et al.
Pageof 7